Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$1.12 - $1.49 $423,440 - $563,327
-378,072 Reduced 74.61%
128,662 $153,000
Q1 2023

May 12, 2023

BUY
$1.19 - $2.19 $570,230 - $1.05 Million
479,185 Added 1739.39%
506,734 $760,000
Q4 2022

Feb 10, 2023

BUY
$1.07 - $1.34 $29,477 - $36,915
27,549 New
27,549 $33,000
Q2 2022

Aug 15, 2022

BUY
$1.13 - $3.69 $18,379 - $60,017
16,265 New
16,265 $14,000
Q4 2020

Feb 08, 2021

SELL
$4.04 - $5.31 $1.14 Million - $1.5 Million
-282,704 Closed
0 $0
Q3 2020

Nov 06, 2020

SELL
$3.64 - $7.76 $2.56 Million - $5.45 Million
-702,025 Reduced 71.29%
282,704 $1.19 Million
Q2 2020

Aug 17, 2020

SELL
$4.78 - $8.26 $194,541 - $336,173
-40,699 Reduced 3.97%
984,729 $6.81 Million
Q2 2020

Aug 11, 2020

BUY
$4.78 - $8.26 $219,445 - $379,208
45,909 Added 4.69%
1,025,428 $22 Million
Q1 2020

May 14, 2020

SELL
$4.0 - $21.53 $183,636 - $988,420
-45,909 Reduced 4.48%
979,519 $3.92 Million
Q4 2019

Feb 06, 2020

BUY
$13.94 - $24.12 $2.36 Million - $4.08 Million
169,253 Added 19.77%
1,025,428 $22 Million
Q3 2019

Nov 12, 2019

BUY
$13.89 - $23.16 $11 Million - $18.3 Million
790,488 Added 1203.42%
856,175 $13 Million
Q2 2019

Aug 14, 2019

BUY
$16.27 - $20.51 $111,677 - $140,780
6,864 Added 11.67%
65,687 $1.27 Million
Q1 2019

May 15, 2019

BUY
$12.61 - $22.33 $337,695 - $597,997
26,780 Added 83.58%
58,823 $1.22 Million
Q3 2018

Nov 08, 2018

BUY
$2.45 - $16.27 $58,905 - $391,179
24,043 Added 300.54%
32,043 $521,000
Q1 2018

May 11, 2018

BUY
$2.99 - $4.44 $23,920 - $35,520
8,000 New
8,000 $24,000

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $177M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.